H
HiFiBiO Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2013
An emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases MoreLess
HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, Massachusetts. The company is committed to improving patient lives with single-cell precision. This means they focus on developing treatments that target individual cells, which can be more effective and have fewer side effects than traditional treatments.
HiFiBiO Therapeutics operates in the biotech market, serving clients in the healthcare sector, including hospitals, clinics, and other medical facilities. Their business model revolves around the development and commercialization of innovative biotech solutions, particularly in the field of drug discovery and development.
One of their key innovations is the Drug Intelligence Science (DIS®) platform, a proprietary translational platform that uses artificial intelligence (AI) to enhance the success rate of drug discovery and development. This platform was recognized as the "AI Innovation of the Year" in the 2023 BioTech Breakthrough Awards, highlighting its potential to revolutionize the biotech industry.
Furthermore, HiFiBiO Therapeutics has received approval from the Chinese National Medical Products Administration (NMPA) for their Investigational New Drug (IND) application for HFB200301, an innovative anti-tumor monoclonal antibody. This is a type of drug that can recognize and attack specific cells in the body, in this case, tumor cells.
The company generates revenue through the development and sale of these innovative biotech solutions, as well as through partnerships with other healthcare and biotech companies.
Keywords: Biotech, Drug Discovery, Drug Development, Single-Cell Precision, Artificial Intelligence, Monoclonal Antibody, Tumor Treatment, Healthcare, Clinical-Stage, Global Company.
Company overview
HiFiBiO Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 63.0
- Investment activity
- 1 companies · latest Oct 2018
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
HiFiBiO Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2021 | $75M | $300M | IDG Capital · B Capital · Hong Kong Science & Technology Parks Corporation · Legend Star | — |
| SERIES COther financing | Aug 2019 | $67M | $268M | IDG Capital · Sequoia | ↗ |
| FundingOther financing | Jan 2019 | $0 | — | Proxima Ventures | ↗ |
| SERIES BOther financing | May 2018 | $38M | $150M | Virtus Inspire Ventures · Sequoia · Legend Star · Proxima Ventures | ↗ |
| SERIES AOther financing | Jan 2017 | $4.2M | $17M | Nest.Bio Labs · Virtus Inspire Ventures | — |
| SERIES AOther financing | Sep 2016 | Nest.Bio Labs | — | ||
| SPINOUTOther financing | Jan 2013 | French National Centre for Scientific Research - CNRS · University of Strasbourg · SATT Conectus · CNRS Innovation | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $12M | 0% | $1.4M | 11.1% |
| 2025 | $12M | 0% | $1.4M | 11.1% |
| 2024 | $12M | 0% | $1.4M | 11.1% |
| 2023 | $12M | +4.2% | $1.4M | 11.1% |
| 2022 | $12M | 0% | $1.4M | 11.6% |
| 2021 | $12M | +6.4% | $1.4M | 11.6% |
| 2020 | $11M | — | $1.4M | 12.3% |
Growth signals
HiFiBiO Therapeutics website traffic
Latest recorded traffic for HiFiBiO Therapeutics is 2.5K monthly website visits, down 30.6% over the last three months. HiFiBiO Therapeutics's team declined 27.1% over the past year.
Comparisons
HiFiBiO Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
HiFiBiO Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
HiFiBiO Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where HiFiBiO Therapeutics has talent and traffic
team presence
In the news
Latest news about HiFiBiO Therapeutics
Recent press, funding announcements, and product moves mentioning HiFiBiO Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about HiFiBiO Therapeutics
An AI-synthesized read of the highest-engagement posts about HiFiBiO Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HiFiBiO Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.